We observed that C1 treatment significantly inhibited cell viability of primary T-ALL cells (Fig. 6b; IC50: 1.72 μM) and of TAIL7 cells (Fig. 6c; IC50: 2.4 μM) even in the presence of high-dose IL-7. The gene discussed is IL7; the disease is acute lymphoblastic leukemia.